Overview

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug

Phase:

PHASE1

Details

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Treatments:

Docetaxel
Nivolumab
Ramucirumab